ArticleDiagnostic and interventional radiology (Ankara, Turkey)
Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.
Article in Diagnostic and interventional radiology (Ankara, Turkey). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.World journal of surgery · 2018Trial
- Yttrium-90 Selective Internal Radiation Therapy for Neuroendocrine Liver Metastases: An Institutional Case Series, Updated Systematic Review, and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Article
- New frontiers in radioembolization.Therapeutic advances in medical oncology · 2024Review
- Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.Tomography (Ann Arbor, Mich.) · 2023Review
- A descriptive analysis of the characteristics, treatment response and prognosis of hepatic dominant solid tumors undergoing selective internal radiation therapy (SIRT).Journal of gastrointestinal oncology · 2022Article
- The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases.Cancers · 2022Review
- Metastatic disease to the liver: Locoregional therapy strategies and outcomes.World journal of clinical oncology · 2021Review
- Liver-Directed Therapies for Neuroendocrine Neoplasms.Current oncology reports · 2021Review
- Verification Study of Residual Activity Measurements After Yttrium-90 Radioembolization with Glass Microspheres.Cardiovascular and interventional radiology · 2020Article
- The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review.Journal of clinical medicine · 2020Review
- Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors.Journal of clinical medicine · 2019Review
- Radioembolization of Hepatocellular Carcinoma with Built-In Dosimetry: FirstTheranostics · 2019Article
- Liver transarterial embolizations in metastatic neuroendocrine tumors.Reviews in endocrine & metabolic disorders · 2017Review
- Current status of transarterial radioembolization.World journal of radiology · 2016Review
- Molecular response assessed by (68)Ga-DOTANOC and survival after (90)Y microsphere therapy in patients with liver metastases from neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2016Article
- How Effective Are Percutaneous Liver-Directed Therapies in Patients with Non-Colorectal Liver Metastases?Viszeralmedizin · 2015Review
- Arterial Therapies of Non-Colorectal Liver Metastases.Viszeralmedizin · 2015Review
- Biodistribution, Pharmacokinetics and Efficacy ofIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe aimed to evaluate the effectiveness and safety of radioembolization with yttrium-90 (90Y) microspheres in cases with unresectable neuroendocrine tumor liver metastases (NETLMs).
methodsThirty patients (mean age, 55 years) underwent resin-based 90Y radioembolization for unresectable NETLM at a single institution between April 2008 and June 2013. Post-treatment tumor response was assessed by cross-sectional imaging using the Response Evaluation Criteria in Solid Tumors (RECIST). Prognostic variables that affected survival were determined.
resultsThe mean follow-up was 23.0±19.4 months and the median overall survival was 39 months (95% CI, 12.6-65.4 months), with one- and two-year survival rates of 71% and 45%, respectively. Imaging follow-up using RECIST at three-month intervals demonstrated partial response in 43%, complete remission in 3%, stable disease in 37%, and progressive disease in 17% of patients. Extent of tumor involvement was found to have a statistically significant influence on overall survival (P = 0.03). The existence of extrahepatic disease at the time of radioembolization, radiographic response, age, and primary neuroendocrine tumor site were not significant prognostic factors.
conclusionThe current study demonstrates the effectiveness and safety of radioembolization for the treatment of unresectable NETLMs. We identified that the extent of tumor involvement has a significant effect on overall survival. The use of imaging methods reflecting metabolic activity or cellularity such as scintigraphy or diffusion-weighted MRI would be more appropriate, for the response evaluation of liver metastases after radioembolization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.